For the latest updates on our ongoing response to COVID-19, please click here.

Medicine Questions

Investors

Contact

Newsroom

An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences

An update about our investigational antiviral for the treatment of COVID-19.

Daniel O’Day - June 29, 2020

Recent Story Posts

Community

National HIV/AIDS and Aging Awareness Day: Coordinating Care for People Living and Aging with HIV

Stories@Gilead - September 18, 2020

Community

Shon Finds New Hope with CAR T Cell Therapy

Stories@Gilead - September 15, 2020

Culture

Working from Home with a 3-Year-Old: A Perspective

Mia Campitelli - September 15, 2020

Recent Press Releases

September 24, 2020
Gilead Sciences Prices $7.25 Billion of Senior Unsecured Notes
September 15, 2020
Gilead’s Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome

Explore More

View Upcoming Events

Company Statements

2019 Year in Review

Twitter

For more information, contact us.

Phone:
1-800-GILEAD-5 (1-800-445-3235) 1-800-GILEAD-5 (1-800-445-3235)

Email:
public_affairs@gilead.com